Kuangli Bio-Tech Holdings（6431）株式概要光麗生物科技控股有限公司は、各種電子製品に使用されるカバーレンズ用パネルを製造・販売している。 詳細6431 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去5年間で収益は年間48.2%減少しました。 意味のある時価総額がありません ( NT$2B )すべてのリスクチェックを見る6431 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$20.8054.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-265m637m2016201920222025202620282031Revenue NT$637.5mEarnings NT$54.6mAdvancedSet Fair ValueView all narrativesKuangli Bio-Tech Holdings Co., Ltd. 競合他社Oriental System TechnologySymbol: TPEX:6819Market cap: NT$2.1bKoryo ElectronicsSymbol: TPEX:8032Market cap: NT$2.2bACON HoldingSymbol: TPEX:3710Market cap: NT$1.8bLitemax ElectronicsSymbol: TPEX:4995Market cap: NT$2.1b価格と性能株価の高値、安値、推移の概要Kuangli Bio-Tech Holdings過去の株価現在の株価NT$20.8052週高値NT$32.0052週安値NT$14.85ベータ0.161ヶ月の変化0.48%3ヶ月変化n/a1年変化19.20%3年間の変化0.97%5年間の変化-33.33%IPOからの変化-33.44%最新ニュースReported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city TaiwanNew Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).最新情報をもっと見るRecent updatesReported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city TaiwanNew Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.お知らせ • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwanお知らせ • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025分析記事 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).お知らせ • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).お知らせ • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).お知らせ • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).分析記事 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.分析記事 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.分析記事 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.分析記事 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period.株主還元6431TW ElectronicTW 市場7D0%7.8%2.6%1Y19.2%197.9%94.7%株主還元を見る業界別リターン: 6431過去 1 年間で197.9 % の収益を上げたTW Electronic業界を下回りました。リターン対市場: 6431は、過去 1 年間で94.7 % のリターンを上げたTW市場を下回りました。価格変動Is 6431's price volatile compared to industry and market?6431 volatility6431 Average Weekly Movement7.2%Electronic Industry Average Movement8.6%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%安定した株価: 6431 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6431の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2012n/aJing-Xiang Linwww.kskl.com.cn光麗生物科技控股有限公司は、各種電子製品に使用されるカバーレンズ用パネルを製造・販売している。同社の製品は、携帯電話やノートパソコンの保護パネル、カメラ、装飾部品、ボタン、タブレットPC、I comタッチパネル、強化ガラスなどの家電パネル、HDプレーヤー、DV、デジタルカメラ、家電製品、MP3、MP4、カーログ、ランプシェード、医療機器などに使用されている。同社は以前、Kuangli Photoelectric Technology Co.2002年に設立されたKuangli Bio-Tech Holdings Co.もっと見るKuangli Bio-Tech Holdings Co., Ltd. 基礎のまとめKuangli Bio-Tech Holdings の収益と売上を時価総額と比較するとどうか。6431 基礎統計学時価総額NT$2.03b収益（TTM）-NT$195.16m売上高(TTM)NT$353.20m5.7xP/Sレシオ-10.4xPER（株価収益率6431 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6431 損益計算書（TTM）収益NT$353.20m売上原価NT$284.01m売上総利益NT$69.20mその他の費用NT$264.36m収益-NT$195.16m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.00グロス・マージン19.59%純利益率-55.25%有利子負債／自己資本比率37.8%6431 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:26終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kuangli Bio-Tech Holdings Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).
Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).
お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).
Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).
Reported Earnings • May 20First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025)First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025).
Reported Earnings • Mar 20Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024)Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024).
お知らせ • Mar 16Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m).
Reported Earnings • Nov 18Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024)Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Sep 03Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024)Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024).
Reported Earnings • May 16First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024)First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024).
Reported Earnings • Mar 19Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023)Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 14Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan
お知らせ • Mar 04Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
分析記事 • Feb 25Kuangli Bio-Tech Holdings Co., Ltd. (TWSE:6431) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedKuangli Bio-Tech Holdings Co., Ltd. ( TWSE:6431 ) shareholders would be excited to see that the share price has had a...
Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023)Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m).
お知らせ • Nov 05Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024
Reported Earnings • Aug 30Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023)Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
New Risk • Aug 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m).
お知らせ • Aug 17Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024
New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m).
お知らせ • May 08+ 1 more updateKuangli Bio-Tech Holdings Co., Ltd. to Report Q1, 2024 Results on May 13, 2024Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q1, 2024 results on May 13, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m).
分析記事 • Mar 22Kuangli Bio-Tech Holdings Co., Ltd.'s (TWSE:6431) Shareholders Might Be Looking For ExitWhen close to half the companies in the Electronic industry in Taiwan have price-to-sales ratios (or "P/S") below 1.6x...
New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m).
New Risk • Nov 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m).
New Risk • Sep 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 07Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022.
分析記事 • Mar 31We're Not Worried About Kuangli Photoelectric Technology's (TPE:6431) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Is New 90 Day High Low • Feb 22New 90-day high: NT$34.10The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period.
分析記事 • Feb 03Did Business Growth Power Kuangli Photoelectric Technology's (TPE:6431) Share Price Gain of 248%?When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...
Is New 90 Day High Low • Jan 29New 90-day high: NT$31.70The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period.
分析記事 • Dec 09We Think Kuangli Photoelectric Technology (TPE:6431) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Oct 29New 90-day low: NT$26.80The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period.
